Chiesi Enters Agreement with Aliada to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
August 16, 2023
Rare Daily Staff
Chiesi Global Rare Diseases said it has entered into a co-development agreement with Aliada Therapeutics to develop treatments for lysosomal storage disorders that can cross the blood-brain barrier.
The research collaboration will focus on multiple enzyme cargoes modified with Aliada’s Modular Delivery (MODEL) platform, which harnesses endogenous brain endothelial cell transport mechanisms to efficiently move large molecule therapeutics across the blood-brain barrier.
Beyond enabling high therapeutic exposure in the brain, the companies said the MODEL platform offers advantages over competing approaches with a broad design landscape that confers the ability to optimize therapeutics for both central nervous system delivery and downstream functionality.
The companies did not disclose financial terms of the agreement.
“Many LSDs have CNS involvement,” said Giacomo Chiesi, head of Chiesi Global Rare Diseases. “With this collaboration, we are expanding our strategy and presence in BBB-crossing technologies and hope to leverage our know-how in LSDs to support the development of an effective and differentiated drug delivery platform.”
Photo: Giacomo Chiesi, head of Chiesi Global Rare Diseases
Sign up for updates straight to your inbox.